Follow-up biopsy in NASH trials: 82%

The authors of this study aimed to quantify the proportion of participants with a valid follow-up biopsy in randomised clinical trials in NASH with at least 1-year follow-up. Forty-one trials were included. The proportion of participants with a valid follow-up biopsy was 82%, without evidence of a difference by location...
PUBLISHED IN: PLoS One 2021

Commentary

The authors of this study aimed to quantify the proportion of participants with a valid follow-up biopsy in randomised clinical trials in NASH with at least 1-year follow-up. Forty-one trials were included. The proportion of participants with a valid follow-up biopsy was 82%, without evidence of a difference by location, trial length, or by allocated treatment group. Biopsy-related serious adverse events occurred in 16 per 1,000 participants, without biopsy-related deaths. These findings can inform adequately-powered trials.

Share the article
Avatar photo

Dr. G. Bozet, MD

Articles: 174

Leave a Reply

Your email address will not be published. Required fields are marked *

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES